Is IPSC or AVBP more profitable?

Century Therapeutics' return on equity of -49.51% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% ArriVent BioPharma N/A -50.26% -46.66%

Does the media prefer IPSC or AVBP?

In the previous week, Century Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.73 beat Century Therapeutics' score of -0.08 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is IPSC or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% First Tracks Biotherapeutics N/A N/A N/A

Does the media favor ABSI or IPSC?

In the previous week, Absci and Absci both had 3 articles in the media. Absci's average media sentiment score of 0.47 beat Century Therapeutics' score of -0.08 indicating that Absci is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MAZE or IPSC more profitable?

Maze Therapeutics' return on equity of -34.94% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -34.94% -30.18% Century Therapeutics N/A -49.51% -38.09%

Does the media refer more to MAZE or IPSC?

In the previous week, Century Therapeutics had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for Maze Therapeutics. Century Therapeutics' average media sentiment score of -0.08 beat Maze Therapeutics' score of -1.05 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, VOR or IPSC?

Vor Biopharma has higher earnings, but lower revenue than Century Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Century Therapeutics $109.16M 3.09 -$9.58M -$0.93 N/A

Is VOR or IPSC more profitable?

Vor Biopharma's return on equity of 0.00% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Century Therapeutics N/A -49.51% -38.09%

Does the media refer more to VOR or IPSC?

In the previous week, Century Therapeutics had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 3 mentions for Century Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.00 beat Century Therapeutics' score of -0.08 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Century Therapeutics (IPSC) Competitors

$1.86 -0.02 (-1.06%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.86 -0.01 (-0.27%)

As of 09/18/2026 07:30 PM Eastern

Compare

IPSC vs. AVBP, TRAX, ABSI, MAZE, and VOR

Should you buy Century Therapeutics stock or one of its competitors? Century Therapeutics's main competitors and comparable companies include ArriVent BioPharma (AVBP), First Tracks Biotherapeutics (TRAX), Absci (ABSI), Maze Therapeutics (MAZE), and Vor Biopharma (VOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Century Therapeutics compare to ArriVent BioPharma?

Century Therapeutics (NASDAQ:IPSC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Century Therapeutics currently has a consensus price target of $4.75, suggesting a potential upside of 155.38%. ArriVent BioPharma has a consensus price target of $44.86, suggesting a potential upside of 55.22%. Given Century Therapeutics' higher possible upside, equities analysts clearly believe Century Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Century Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.09	-$9.58M	-$0.93	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Century Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.73 beat Century Therapeutics' score of -0.08 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Century Therapeutics' return on equity of -49.51% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
ArriVent BioPharma	N/A	-50.26%	-46.66%

Century Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Summary

Century Therapeutics beats ArriVent BioPharma on 10 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to First Tracks Biotherapeutics?

Century Therapeutics (NASDAQ:IPSC) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for First Tracks Biotherapeutics and 3 mentions for Century Therapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.33 beat Century Therapeutics' score of -0.08 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
First Tracks Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

First Tracks Biotherapeutics' return on equity of 0.00% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
First Tracks Biotherapeutics	N/A	N/A	N/A

50.2% of Century Therapeutics shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Century Therapeutics currently has a consensus target price of $4.75, indicating a potential upside of 155.38%. First Tracks Biotherapeutics has a consensus target price of $66.55, indicating a potential upside of 72.40%. Given Century Therapeutics' higher possible upside, equities research analysts clearly believe Century Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

First Tracks Biotherapeutics has lower revenue, but higher earnings than Century Therapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.09	-$9.58M	-$0.93	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

Summary

Century Therapeutics and First Tracks Biotherapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Century Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Century Therapeutics has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	591.44	-$115.18M	-$0.80	N/A
Century Therapeutics	$109.16M	3.09	-$9.58M	-$0.93	N/A

52.1% of Absci shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 10.5% of Absci shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Absci currently has a consensus price target of $13.71, suggesting a potential upside of 42.12%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 155.38%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Absci and Absci both had 3 articles in the media. Absci's average media sentiment score of 0.47 beat Century Therapeutics' score of -0.08 indicating that Absci is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Century Therapeutics' return on equity of -49.51% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Century Therapeutics	N/A	-49.51%	-38.09%

Absci has a beta of 2.42, meaning that its stock price is 142% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Summary

Absci beats Century Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

50.2% of Century Therapeutics shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Century Therapeutics has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	7.47	-$131.12M	-$2.52	N/A
Century Therapeutics	$109.16M	3.09	-$9.58M	-$0.93	N/A

In the previous week, Century Therapeutics had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for Maze Therapeutics. Century Therapeutics' average media sentiment score of -0.08 beat Maze Therapeutics' score of -1.05 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Maze Therapeutics' return on equity of -34.94% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Century Therapeutics	N/A	-49.51%	-38.09%

Maze Therapeutics currently has a consensus target price of $66.00, suggesting a potential upside of 193.07%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 155.38%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maze Therapeutics is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Maze Therapeutics beats Century Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vor Biopharma has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

In the previous week, Century Therapeutics had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 3 mentions for Century Therapeutics and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.00 beat Century Therapeutics' score of -0.08 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma currently has a consensus target price of $43.38, indicating a potential upside of 102.69%. Century Therapeutics has a consensus target price of $4.75, indicating a potential upside of 155.38%. Given Century Therapeutics' higher probable upside, analysts clearly believe Century Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Vor Biopharma has higher earnings, but lower revenue than Century Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Century Therapeutics	$109.16M	3.09	-$9.58M	-$0.93	N/A

Vor Biopharma's return on equity of 0.00% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Century Therapeutics	N/A	-49.51%	-38.09%

Summary

Vor Biopharma beats Century Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$340.42M	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-2.00	14.30	275.79	25.40
Price / Sales	3.09	1,415.50	695.58	114.44
Price / Cash	141.35	110.75	77.42	51.66
Price / Book	1.02	15.45	10.46	6.33
Net Income	-$9.58M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-4.12%	-1.21%	0.59%	1.12%
1 Month Performance	-11.85%	-4.42%	-2.01%	-2.67%
1 Year Performance	289.77%	37.81%	18.09%	6.01%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	1.4243 of 5 stars	$1.86 -1.1%	$4.75 +155.4%	+266.9%	$340.42M	$109.16M	N/A	78	High Trading Volume
AVBP ArriVent BioPharma	2.4932 of 5 stars	$28.05 -1.8%	$44.86 +59.9%	+55.5%	$1.38B	N/A	N/A	77	Positive News
TRAX First Tracks Biotherapeutics	2.6322 of 5 stars	$38.17 +1.6%	$63.00 +65.1%	N/A	$1.36B	N/A	N/A	104	News Coverage Analyst Forecast Gap Up
ABSI Absci	2.7582 of 5 stars	$7.89 -2.5%	$13.71 +73.9%	+258.7%	$1.35B	$1.56M	N/A	140
MAZE Maze Therapeutics	2.0569 of 5 stars	$24.27 -1.6%	$66.00 +171.9%	-4.1%	$1.35B	$20M	N/A	141	Negative News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. AVBP, TRAX, ABSI, MAZE, and VOR

How does Century Therapeutics compare to ArriVent BioPharma?

Summary

How does Century Therapeutics compare to First Tracks Biotherapeutics?

Summary

How does Century Therapeutics compare to Absci?

Summary

How does Century Therapeutics compare to Maze Therapeutics?

Summary

How does Century Therapeutics compare to Vor Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. AVBP, TRAX, ABSI, MAZE, and VOR

How does Century Therapeutics compare to ArriVent BioPharma?

Do analysts rate IPSC or AVBP?

Which has preferable valuation and earnings, IPSC or AVBP?

Do institutionals and insiders have more ownership in IPSC or AVBP?

Does the media prefer IPSC or AVBP?

Is IPSC or AVBP more profitable?

Which has more risk and volatility, IPSC or AVBP?

Summary

How does Century Therapeutics compare to First Tracks Biotherapeutics?

Does the media refer more to IPSC or TRAX?

Is IPSC or TRAX more profitable?

Do institutionals & insiders believe in IPSC or TRAX?

Do analysts rate IPSC or TRAX?

Which has better valuation and earnings, IPSC or TRAX?

Summary

How does Century Therapeutics compare to Absci?

Which has preferable earnings & valuation, ABSI or IPSC?

Do institutionals & insiders hold more shares of ABSI or IPSC?

Do analysts rate ABSI or IPSC?

Does the media favor ABSI or IPSC?

Is ABSI or IPSC more profitable?

Which has more volatility and risk, ABSI or IPSC?

Summary

How does Century Therapeutics compare to Maze Therapeutics?

Do institutionals and insiders hold more shares of MAZE or IPSC?

Which has better valuation and earnings, MAZE or IPSC?

Does the media refer more to MAZE or IPSC?

Which has more risk and volatility, MAZE or IPSC?

Is MAZE or IPSC more profitable?

Do analysts prefer MAZE or IPSC?

Summary

How does Century Therapeutics compare to Vor Biopharma?

Do institutionals & insiders believe in VOR or IPSC?

Which has more volatility and risk, VOR or IPSC?

Does the media refer more to VOR or IPSC?

Do analysts recommend VOR or IPSC?

Which has higher valuation & earnings, VOR or IPSC?

Is VOR or IPSC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools